Pacira BioSciences' Equity Average fell 883.32% to $742.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $742.5 million, marking a year-over-year decrease of 883.32%. This contributed to the annual value of $824.2 million for FY2024, which is 20.29% up from last year.
Per Pacira BioSciences' latest filing, its Equity Average stood at $742.5 million for Q3 2025, which was down 883.32% from $778.2 million recorded in Q2 2025.
Pacira BioSciences' Equity Average's 5-year high stood at $885.7 million during Q2 2024, with a 5-year trough of $635.3 million in Q1 2021.
For the 5-year period, Pacira BioSciences' Equity Average averaged around $768.7 million, with its median value being $771.5 million (2023).
In the last 5 years, Pacira BioSciences' Equity Average skyrocketed by 7554.61% in 2021 and then crashed by 1214.45% in 2025.
Pacira BioSciences' Equity Average (Quarter) stood at $724.5 million in 2021, then rose by 6.63% to $772.6 million in 2022, then grew by 10.13% to $850.8 million in 2023, then fell by 10.21% to $764.0 million in 2024, then fell by 2.81% to $742.5 million in 2025.
Its last three reported values are $742.5 million in Q3 2025, $778.2 million for Q2 2025, and $788.4 million during Q1 2025.

Peer Comparison

Historic Data

Download Data 🔒

Date	Value